134 related articles for article (PubMed ID: 33537546)
1. Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays.
Liang Y; Jackson JW; Woodle SA; Surov SS; Parunov LA; Scott DE; Weinstein M; Lee TK; Ovanesov MV
Res Pract Thromb Haemost; 2021 Jan; 5(1):211-222. PubMed ID: 33537546
[TBL] [Abstract][Full Text] [Related]
2. Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.
Behr-Gross ME; Le Tallec D; Sinitskaya N; Milne C; Etscheid M
Pharmeur Bio Sci Notes; 2024; 2024():27-75. PubMed ID: 38533680
[TBL] [Abstract][Full Text] [Related]
3. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
Komenda M; Stadler D; Malinas T; Moses M; Pragst I; Herzog E; Schmutz P; Minnig K; El Menyawi I
Vox Sang; 2014 Jul; 107(1):26-36. PubMed ID: 24329163
[TBL] [Abstract][Full Text] [Related]
5. Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.
Xu Y; Liang Y; Parunov L; Despres D; Eckhaus M; Scott D; Ovanesov M; Struble EB
Thromb J; 2020 Nov; 18(1):32. PubMed ID: 33292285
[TBL] [Abstract][Full Text] [Related]
6. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation.
Kang GB; Huber A; Lee J; Kim MJ; Bang E; Hong J; Park S
Front Cardiovasc Med; 2023; 10():1253177. PubMed ID: 38075963
[TBL] [Abstract][Full Text] [Related]
7. Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation.
Parunov LA; Liang Y; Lu Q; Shibeko AM; Tucker EI; Lee TK; Ataullakhanov FI; Scott DE; Ovanesov MV
Blood Adv; 2023 Jun; 7(11):2622-2631. PubMed ID: 36724509
[TBL] [Abstract][Full Text] [Related]
8. Thrombin generation test based on a 96-channel pipettor for evaluation of FXIa procoagulant activity in pharmaceuticals.
Parunov LA; Shea ME; Liang Y; Surov SS; Chattopadhyay M; Lee TK; Scott DE; Ovanesov MV
Nat Protoc; 2021 Aug; 16(8):3981-4003. PubMed ID: 34215864
[TBL] [Abstract][Full Text] [Related]
9. Role of platelets in regulating activated coagulation factor XI activity.
Reitsma SE; Pang J; Raghunathan V; Shatzel JJ; Lorentz CU; Tucker EI; Gruber A; Gailani D; McCarty OJT; Puy C
Am J Physiol Cell Physiol; 2021 Mar; 320(3):C365-C374. PubMed ID: 33471623
[TBL] [Abstract][Full Text] [Related]
10. Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products.
Wilmot HV; Gray E
Vox Sang; 2021 Jul; 116(6):656-664. PubMed ID: 33277936
[TBL] [Abstract][Full Text] [Related]
11. The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies.
Tarandovskiy ID; Ovanesov MV
Thromb Res; 2024 Jan; 233():189-199. PubMed ID: 38101192
[TBL] [Abstract][Full Text] [Related]
12. Comparative Thrombin Generation in Animal Plasma: Sensitivity to Human Factor XIa and Tissue Factor.
Liang Y; Tarandovskiy I; Surov SS; Ovanesov MV
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629101
[TBL] [Abstract][Full Text] [Related]
13. Predictive value for increased activated factor XI activity in acute venous thromboembolism.
Nagy M; Robles AP; Visser M; Koeck T; Ten Cate V; Ten Cate-Hoek AJ; Schwers S; Heitmeier S; Ten Cate H; Wild PS; Spronk HMH
J Thromb Haemost; 2023 Jun; 21(6):1610-1622. PubMed ID: 37003466
[TBL] [Abstract][Full Text] [Related]
14. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.
Park DH; Kang GB; Kang DE; Hong JW; Lee MG; Kim KY; Han JW
Biologicals; 2017 Jan; 45():1-8. PubMed ID: 27876270
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
[TBL] [Abstract][Full Text] [Related]
16. An application of mass spectrometry for quality control of biologicals: Highly sensitive profiling of plasma residuals in human plasma-derived immunoglobulin.
Limonier F; Van Steendam K; Waeterloos G; Brusselmans K; Sneyers M; Deforce D
J Proteomics; 2017 Jan; 152():312-320. PubMed ID: 27894965
[TBL] [Abstract][Full Text] [Related]
17. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.
Waters EK; Hilden I; Sørensen BB; Ezban M; Holm PK
J Thromb Haemost; 2015 Nov; 13(11):2041-52. PubMed ID: 26340413
[TBL] [Abstract][Full Text] [Related]
18. The mechanism underlying activation of factor IX by factor XIa.
Gailani D; Geng Y; Verhamme I; Sun MF; Bajaj SP; Messer A; Emsley J
Thromb Res; 2014 May; 133 Suppl 1(0 1):S48-51. PubMed ID: 24759143
[TBL] [Abstract][Full Text] [Related]
19. Effect of factor XI inhibition on tumor cell-induced coagulation activation.
Mäder J; Rolling CC; Voigtländer M; Schulenkorf A; Lehr C; Regenhardt J; Bokemeyer C; Beckmann L; Langer F
J Thromb Haemost; 2024 Jan; 22(1):199-212. PubMed ID: 37751848
[TBL] [Abstract][Full Text] [Related]
20. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies.
Ma L; Sun P; Lin FZ; Diao G; Li CQ
Genet Mol Res; 2013 Jul; 12(3):2556-61. PubMed ID: 23315876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
